Rabia Hande Avcı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rabia Hande Avcı has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Avci
Department of Cardiology, Kastamonu University Faculty of Medicine, Kastamonu, Turkey
1 shared publication - Ahmet Bertug Celik
Karabük University, Faculty of Medicine, Department of Cardiology, Karabük, Türkiye
1 shared publication - Ahmet Furkan Süner
Department of Public Health, Faculty of Medicine, Düzce University, 81620 Düzce, Türkiye
1 shared publication - Alper Bozkurt
Karabük University, Faculty of Medicine, Department of Cardiology, Karabük, Türkiye
1 shared publication - Bahar Taşdelen
Department of Biostatistics and Medical Informatics, Faculty of Medicine, Mersin University, Mersin, Türkiye
1 shared publication - Bora Çekmen
Department of Emergency Medicine, Faculty of Medicine, Karabuk University, Karabuk, Turkiye
1 shared publication
Latest Publications
- 6 July 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 261, 109024
Respiratory muscle strength, functional exercise capacity, and muscle oxygenation differences between COPD, PRISM, and healthy controls
- 6 July 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 261, 109024
Respiratory muscle strength, functional exercise capacity, and muscle oxygenation differences between COPD, PRISM, and healthy controls
- 1 July 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (7) , 666-670
Biomarkers in prediction of pulmonary thromboembolism in COVID-19 infection?
Aim This study aimed to investigate whether a biomarker can indicate pulmonary thromboembolism (PTE), which plays a major role in the severity and mortality of COVID-19, at the start of treatment. Materials and Methods A total of 160 adult patients who were admitted to the Chest Diseases Clinic between April 2020 and April 2021 were retrospectively included in this study. The patients were divided into three groups: COVID PCR + PTE + (group 1), COVID PCR – PTE + (group 2), and PCR + PTE – (group 3). Demographic data and biomarker levels, including D-dimer, ferritin, fibrinogen, troponin-I, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), were obtained from the hospital’s electronic data system. Statistical analyses were performed using the STATISTICA 13.0 software package. Results No statistically significant differences were found between the patient groups regarding median age, sex, D-dimer, or troponin-I levels (p>0.05). Statistically significant differences were observed between some groups in ferritin, fibrinogen, CRP, NLR, and PLR values (p<0.05). Conclusion In this study evaluating the potential of biomarkers to indicate pulmonary thromboembolism at the time of diagnosis in SARS-CoV-2 patients, the parameters that showed statistically significant differences were not considered reliable for early detection of PTE, as they may be influenced by multiple factors. Given the limited current data on COVID-19, further studies are needed to clarify these findings.
- 1 July 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (7) , 666-670
Biomarkers in prediction of pulmonary thromboembolism in COVID-19 infection?
Aim This study aimed to investigate whether a biomarker can indicate pulmonary thromboembolism (PTE), which plays a major role in the severity and mortality of COVID-19, at the start of treatment. Materials and Methods A total of 160 adult patients who were admitted to the Chest Diseases Clinic between April 2020 and April 2021 were retrospectively included in this study. The patients were divided into three groups: COVID PCR + PTE + (group 1), COVID PCR – PTE + (group 2), and PCR + PTE – (group 3). Demographic data and biomarker levels, including D-dimer, ferritin, fibrinogen, troponin-I, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), were obtained from the hospital’s electronic data system. Statistical analyses were performed using the STATISTICA 13.0 software package. Results No statistically significant differences were found between the patient groups regarding median age, sex, D-dimer, or troponin-I levels (p>0.05). Statistically significant differences were observed between some groups in ferritin, fibrinogen, CRP, NLR, and PLR values (p<0.05). Conclusion In this study evaluating the potential of biomarkers to indicate pulmonary thromboembolism at the time of diagnosis in SARS-CoV-2 patients, the parameters that showed statistically significant differences were not considered reliable for early detection of PTE, as they may be influenced by multiple factors. Given the limited current data on COVID-19, further studies are needed to clarify these findings.
- 4 May 2026
- Published by Elsevier in Heart & Lung
- Vol. 79, 102825
Prognostic power of electrical risk score in acute pulmonary embolism: insights beyond conventional risk stratification
- 4 May 2026
- Published by Elsevier in Heart & Lung
- Vol. 79, 102825
Prognostic power of electrical risk score in acute pulmonary embolism: insights beyond conventional risk stratification
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (8) , 423-430
15. CA125 as a Biomarker for Identifying Disease Severity and Right Ventricular Dysfunction in Obstructive Sleep Apnea
Background: Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk, particularly through right ventricular (RV) dysfunction. Cancer antigen 125 (CA125), a biomarker traditionally used in ovarian cancer, has shown potential as an indicator of RV dysfunction. This study aims to compare CA125 levels between OSA patients and controls and to evaluate its association with disease severity and subclinical RV dysfunction. Methods: This cross-sectional study included sixty OSA patients, divided into severe (apnea-hypopnea index [AHI] ≥ 30) and non-severe groups, and sixty age- and sex-matched controls. Cancer antigen 125 levels were assessed together with echocardiographic markers. Regression analysis identified predictors of severe OSA, and receiver operating characteristic (ROC) analysis assessed the diagnostic performance of CA125. Results: Cancer antigen 125 levels were significantly elevated in severe OSA patients compared to non-severe and control groups (median 34.3 vs. 12.9 vs. 10.3 U/mL, P < .001). Cancer antigen 125 correlated with RV fractional area change (RV-FAC) (r = −0.496, P < .001), tricuspid annular plane systolic excursion (TAPSE) (r = −0.285, P = .027), and AHI (r = 0.581, P < .001). Regression analysis identified CA125 (odds ratio [OR] = 1.259, 95% con-fidence interval [CI]: 1.102-1.438, P = .001) and TAPSE (OR= 0.425, 95% CI: 0.217-0.834, P = .013) as independent predictors of severe OSA. ROC analysis showed that CA125 could effectively predict RV dysfunction (area under the curve [AUC] = 0.857) and severe OSA (AUC = 0.804). Conclusion: Elevated CA125 levels are associated with increased disease severity and subclinical RV dysfunction in OSA, suggesting its potential as a biomarker for early cardiac involvement.
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (8) , 423-430
Open Access15. CA125 as a Biomarker for Identifying Disease Severity and Right Ventricular Dysfunction in Obstructive Sleep Apnea
Background: Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk, particularly through right ventricular (RV) dysfunction. Cancer antigen 125 (CA125), a biomarker traditionally used in ovarian cancer, has shown potential as an indicator of RV dysfunction. This study aims to compare CA125 levels between OSA patients and controls and to evaluate its association with disease severity and subclinical RV dysfunction. Methods: This cross-sectional study included sixty OSA patients, divided into severe (apnea-hypopnea index [AHI] ≥ 30) and non-severe groups, and sixty age- and sex-matched controls. Cancer antigen 125 levels were assessed together with echocardiographic markers. Regression analysis identified predictors of severe OSA, and receiver operating characteristic (ROC) analysis assessed the diagnostic performance of CA125. Results: Cancer antigen 125 levels were significantly elevated in severe OSA patients compared to non-severe and control groups (median 34.3 vs. 12.9 vs. 10.3 U/mL, P < .001). Cancer antigen 125 correlated with RV fractional area change (RV-FAC) (r = −0.496, P < .001), tricuspid annular plane systolic excursion (TAPSE) (r = −0.285, P = .027), and AHI (r = 0.581, P < .001). Regression analysis identified CA125 (odds ratio [OR] = 1.259, 95% con-fidence interval [CI]: 1.102-1.438, P = .001) and TAPSE (OR= 0.425, 95% CI: 0.217-0.834, P = .013) as independent predictors of severe OSA. ROC analysis showed that CA125 could effectively predict RV dysfunction (area under the curve [AUC] = 0.857) and severe OSA (AUC = 0.804). Conclusion: Elevated CA125 levels are associated with increased disease severity and subclinical RV dysfunction in OSA, suggesting its potential as a biomarker for early cardiac involvement.